Authors
Latest:
Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast CancerSarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary InfectionThis case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.
Latest:
Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-USIbrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
Latest:
Treatment Decision-Making in Colon CancerAparna Parikh, MD, and the Oncology Brothers have a comprehensive discussion on treatment decision-making practices for patients with colon cancer, highlighting considerations such as high microsatellite instability and refractory disease.
Latest:
Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is NewJonathan R. Day, MD, PharmD, and Brian K. Link, MD, give their perspective on emerging treatments for follicular lymphoma.
Latest:
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and LeukemiaExperts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
Latest:
Nivolumab May Enhance Outcomes with SOC Therapy for Locally Advanced HNSCCThe phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Latest:
Bispecifics in R/R MM: Key TakeawaysPanelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices to ensure equitable access to bispecific therapies, highlighting that it’s an exciting time in myeloma treatment with patient-friendly options that can be administered closer to home, and concluding that virtually no patient should be denied exposure to bispecific therapy before discontinuing treatment, while anticipating that de-escalated Q4 weekly schedules and trispecific agents will transform current practice patterns in the coming years.
Latest:
Oncology Peer Review On-The-Go: Integrative Oncology in Young Population with Breast CancerYancey Warren, Jr, MD, MAT, and Lejla Hadzikadic-Gusic, MD, MSc, spoke with CancerNetwork® about their work investigating the use of integrative oncology services among young patients diagnosed with breast cancer.
Latest:
Advancing CML Management Towards an Ideal Patient JourneyThe panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
The Future of CAR-T: Advancing Myeloma Treatment StrategiesPanelists discuss the evolving role of chimeric antigen receptor T-cell therapy in earlier lines of treatment for multiple myeloma, with a focus on upcoming advances for patients with standard-risk disease and the impact of multidisciplinary collaboration on improving patient care and outcomes.
Latest:
The Management of Relapsed and Refractory Multiple MyelomaZhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.
Latest:
Taking a “Cross-Cutting Approach” With Cancer VaccinationsCancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Best Practices for the Medical Oncology BoardsA group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Latest:
Advancing Glioblastoma Research Through a Phase 3 Niraparib TrialInvestigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.
